Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Tax Provisions (2020 - 2025)

Historic Tax Provisions for Ironwood Pharmaceuticals (IRWD) over the last 8 years, with Q3 2025 value amounting to $27.9 million.

  • Ironwood Pharmaceuticals' Tax Provisions rose 10359.98% to $27.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $65.0 million, marking a year-over-year decrease of 1296.75%. This contributed to the annual value of $64.3 million for FY2024, which is 2297.25% down from last year.
  • Per Ironwood Pharmaceuticals' latest filing, its Tax Provisions stood at $27.9 million for Q3 2025, which was up 10359.98% from $14.2 million recorded in Q2 2025.
  • Ironwood Pharmaceuticals' Tax Provisions' 5-year high stood at $32.1 million during Q4 2023, with a 5-year trough of -$336.9 million in Q2 2021.
  • In the last 5 years, Ironwood Pharmaceuticals' Tax Provisions had a median value of $16.7 million in 2022 and averaged -$3.1 million.
  • Per our database at Business Quant, Ironwood Pharmaceuticals' Tax Provisions skyrocketed by 399722.22% in 2022 and then crashed by 8778.51% in 2025.
  • Over the past 5 years, Ironwood Pharmaceuticals' Tax Provisions (Quarter) stood at $4.9 million in 2021, then skyrocketed by 377.55% to $23.4 million in 2022, then surged by 37.18% to $32.1 million in 2023, then plummeted by 32.34% to $21.7 million in 2024, then rose by 28.65% to $27.9 million in 2025.
  • Its Tax Provisions stands at $27.9 million for Q3 2025, versus $14.2 million for Q2 2025 and $1.1 million for Q1 2025.